Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes

Bonnefoi, Hervé; MacGrogan, Gaetan; Poncet, Coralie; Iggo, Richard; Pommeret, Fanny; Grellety, Thomas; Larsimont, Denis; Bécette, Véronique; Kerdraon, Olivier; Bibeau, Frédéric; Ghnassia, Jean-Pierre; Picquenot, Jean-Michel; Thomas, Jeremy; Tille, Jean-Christophe; Slaets, Leen; Bodmer, Alexandre; Bergh, Jonas; Cameron, David

doi:10.1038/s41416-019-0420-y

Scientific article

English

Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes

ContributorsBonnefoi, Hervé; MacGrogan, Gaetan; Poncet, Coralie; Iggo, Richard; Pommeret, Fanny; Grellety, Thomas; Larsimont, Denis; Bécette, Véronique; Kerdraon, Olivier; Bibeau, Frédéric; Ghnassia, Jean-Pierre; Picquenot, Jean-Michel; Thomas, Jeremy; Tille, Jean-Christophe; Slaets, Leen; Bodmer, Alexandre; Bergh, Jonas; Cameron, David

Published inBritish Journal of Cancer, vol. 120, no. 9, p. 913-921

Publication date2019

Abstract

We explored, within the EORTC10994 study, the outcomes for patients with molecular apocrine (MA) breast cancer, and defined immunohistochemistry (IHC) as androgen-receptor (AR) positive, oestrogen (ER) and progesterone (PR) negative. We also assessed the concordance between IHC and gene expression arrays (GEA) in the identification of MA cancers.

Affiliation entities

Faculté de médecine / Section de médecine fondamentale / Département de pathologie et immunologie

Citation (ISO format)

BONNEFOI, Hervé et al. Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes. In: British Journal of Cancer, 2019, vol. 120, n° 9, p. 913–921. doi: 10.1038/s41416-019-0420-y